Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once‐weekly dipeptidyl peptidase‐4 inhibitor, in healthy Japanese men

AIMS/INTRODUCTION: Omarigliptin is a novel, potent, long‐acting oral dipeptidyl peptidase‐4 inhibitor being developed as a once‐weekly (q.w.) treatment for type 2 diabetes mellitus patients, with 25 mg and 12.5 mg tablets recently being approved as market formulations in Japan. MATERIALS AND METHODS...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Diabetes Investig
Main Authors: Tsuchiya, Saori, Friedman, Evan, Addy, Carol, Wakana, Akira, Tatosian, Daniel, Matsumoto, Yuki, Suzuki, Hideyo, Kauh, Eunkyung
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5217871/
https://ncbi.nlm.nih.gov/pubmed/27182005
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.12538
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados